Raf and VEGF: Emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors

Leukemia

Volumn 19, Issue 1, 2005, Pages 18-26

  Hamden, K E ^a   Whitman, A G ^a   Ford, P W ^a   Shelton, J G ^a   McCubrey, J A ^a   Akula, S M ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Angiogenesis; HHV 8; KSHV; PEL; Raf; VEGF

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; AAL 993; ANGIOZYME; ARRY 142886; AZD 6244; BEVACIZUMAB; CGP 69846A; CP 547 632; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GAMMA INTERFERON; GW 5074; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; L 778 450; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; ONCOSTATIN M; PROTEIN KINASE INHIBITOR; RAF PROTEIN; SCATTER FACTOR; SEMAXANIB; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANGIOGENESIS; AUTOCRINE EFFECT; CELL GROWTH; CLINICAL FEATURE; DRUG ACTIVITY; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; MICROENVIRONMENT; MULTIPLE CANCER; PARACRINE SIGNALING; PATHOGENESIS; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; VIRUS CARCINOGENESIS;

EID: 11844296672     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403532     Document Type: Review

References (101)

1. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-1869.
2. Gallo RC. HIV-1, HHV-8, and Kaposi's sarcoma.J Hum Virol 1998; 1: 185-186.
3. Verma SC, Roberson ES. Molecular biology and pathogenesis of Kaposi sarcoma-associated herpesvirus. FEMS Microbiol Lett 2003; 222: 155-163.
4. Sarid R, Klepfish A, Schattner A. Virology, pathogenetic mechanisms, and associated diseases of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8). Mayo Clin Proc 2002; 77: 941-949.
5. Ablashi DV, Chatlynne LG, Whitman Jr JE, Cesarman E. Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiol Rev 2002; 15: 439-464.
6. Ensoli B, Sgadari C, Barillari G, Sirianni MC, Sturzl M, Monini P. Biology of Kaposi's sarcoma. Eur J Cancer 2001; 37: 1251-1269.
7. Kempf W, Cathomas G, Burg G, Trueb RM. Micronodular Kaposi's sarcoma - a new variant of classic-sporadic Kaposi's sarcoma. Dermatology 2004; 208: 255-258.
8. Schulz TF. KSHV/HHV8-associated lymphoproliferations in the AIDS setting. Eur J Cancer 2001; 37: 1217-1226.
9. Ensoli B, Sturzl M, Monini P. Cytokine-mediated growth promotion of Kaposi's sarcoma and primary effusion lymphoma. Cancer Biol 2000; 10: 367-381.
10. Geraminejad P, Memar O, Aronson I, Rady PL, Hengge U, Tyring SK. Kaposi's sarcoma and other manifestations of human herpesvirus 8. J Am Acad Dermatol 2002; 47: 641-655.
11. Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet 2002; 2: 344-352.
12. Cesarman E, Mesri EA, Gershengorn MC. Viral G protein-coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia. J Exp Med 2000; 191: 417-421.
13. Hoischen SH, Vollmer P, Marz P, Ozbek S, Gotze KS, Peschel C et al. Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells. Eur J Biochem 2000; 267: 3604-3612.
14. Yao L, Salvucci O, Cardones AR, Hwang ST, Aoki Y, De La Luz Sierra M et al. Selective expression of stromal-derived factor-1 in the capillary vascular endothelium plays a role in Kaposi sarcoma pathogenesis. Blood 2003; 102: 3900-3905.
15. Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, Tosato G. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 2002; 99 2703-2711.
16. Stevenson FT, Turck J, Locksley RM, Lovett DH. The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncoprotein. Proc Natl Acad Sci USA 1997; 94: 508-513.
17. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 1994; 8: 1314-1325.
18. Simonart T, Van Vooren JP. Interleukin-1 beta increases the BCL-2/BAX ratio in Kaposi's sarcoma cells. Cytokine 2002; 19: 259-266.
19. Estrov Z, Talpaz M. Role of interleukin-1 beta converting enzyme (ICE) in acute myelogenous leukemia cell proliferation and programmed cell death. Leukemia Lymphoma 1997; 24: 379-391.
20. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002; 4: S233-S242.
21. Mukaida N, Harada A, Matsushima K. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev 1998; 9: 9-23.
22. van Eeden SF, Terashima T. Interleukin 8 (IL-8) and the release of leukocytes from the bone marrow. Leukemia Lymphoma 2000; 37: 259-271.
23. Singh RK, Varney ML. IL-8 expression in malignant melanoma: implications in growth and metastasis. Histol Histopathol 2000; 15: 843-849.
24. Bian X, Chen Z, Guo D, Du L, Xin R, Shi J. Expression of angiogenic factors and cell cycle regulation factors in human glioblastoma cell line SHG-44. Zhonghua Bing Li Xue Za Zhi 1999; 28: 178-181.
25. Schecter AD, Berman AB, Yi L, Ma H, Daly CM, Soejima K et al. MCP-1-dependent signaling in CCR2-/- aortic smooth muscle cells. J Leukocyte Biol 2004; 75: 1079-1085.
26. Verma A, Platanias LC. Signaling via the interferon-α receptor in chronic myelogenous leukemia cells. Leukemia Lymphoma 2002; 43: 703-709.
27. Chang J, Renne R, Dittmer D, Ganem D. Inflammatory cytokines and the reactivation of Kaposi's sarcoma associated herpesvirus lytic replication. Virology 2000; 266: 17-25.
28. Bayas A, Gold R. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment. J Neurol 2003; 250: IV3-IV8.
29. Coclet-Ninin J, Dayer JM, Burger D. Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Networks 1997; 8: 345-349.
30. Young HA. Regulation of interferon-gamma gene expression. J Interferon Cytokine Res 1996; 16: 563-568.
31. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukocyte Biol 2004; 75: 163-189.
32. Geppert TD, Whitehurst CE, Thompson P, Beutler B. Lipopolysaccharide signals activation of tumor necrosis factor biosynthesis through the ras/raf-1/MEK/MAPK pathway. Mol Med 1994; 1: 93-103.
33. McDevitt H, Munson S, Ettinger R, Wu A. Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity. Arthritis Res 2002; 4: S141-S152.
34. Thompson MP, Aggarwal BB, Shishodia S, Estrov Z, Kurzrock R. Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1. Leukemia 2003; 17: 2196-2201.
35. Chin D, Boyle GM, Parsons PG, Coman WB. What is transforming growth factor-beta (TGF-beta)? Br J Plast Surg 2004; 57: 215-221.
36. Kim SJ, Letterio J. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. Leukemia 2003; 17: 1731-1737.
37. Aoki Y, Tosato G. Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas. Leukemia Lymphoma 2001; 41: 229-237.
38. Cheng AC, Stephens DP, Currie BJ. Granulocyte colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev 2003; 4: CD004400.
39. Masood R, Cesarman E, Smith DL, Gill PS, Flore O. Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. Am J Pathol 2002; 160: 23-29.
40. Raab G, Higashiyama S, Hetelekidis S, Abraham JA, Damm D, Ono M et al. Biosynthesis and processing by phorbo ester of the cells surface associated precursor form of heparin-binding EGF-like growth factor. Biochem Biophys Res Commun 1994; 204: 592-597.
41. Higashiyama S, Iwamoto R, Goishi K, Raab G, Taniguchi N, Klagsbrun M et al. The membrane protein CD9/DRAP27 potentiates the justacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol 1995; 128 929-938.
42. Raab G, Klagsbrun M. Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1997; 1333: F179-F199.
43. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-3167.
44. Thompson SA, Higashiyamanll S, Wood K, Pollitt NS, Damm D, McEnroe G et al. Characterization of sequences within heparin-binding EGF-like growth factor that mediate interaction with heparin. J Biol Chem 1994; 269: 2541-2549.
45. Hamilton JA. GM-CSF in inflammation and autoimmunity. Trends Immunol 2002; 23: 403-408.
46. Weidermann H, Mittermayr M, Hoffmann G, Schobersberger W. Recombinant granulocyte colony-stimulating factor (G-CSF) in infectious diseases: still a debate. Wien Klin Wochenschr 2001; 113: 90-96.
47. De Falco S, Gigante B, Persico MG. Structure and function of placental growth factor. Trends Cardiovasc Med 2002; 12: 241-246.
48. Lamszus K, Laterra J, Westphal M, Rosen EM. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci 1999; 17: 517-530.
49. Naidu YM, Rosen EM, Zitnick R, Goldberg I, Park M, Naujokas M et al. Role of scatter factor in the pathogenesis of AIDS-related Kaposi sarcoma. Proc Natl Acad Sci USA 1994; 91: 5281-5285.
50. George D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol 2001; 28: 27-33.
51. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 2003; 149: 39-52.
52. Pelletier JP, Martel-Pelletier J. Oncostatin M: foe or friend? Arthritis Rheum 2003; 48: 3301-3303.
53. Mercader M, Taddeo B, Panella JR, Chandran B, Nickoloff BJ, Foreman KE. Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. Am J Pathol 2000; 156: 1961-1971.
54. Wong RW, Guillaud L. The role of epidermal growth factor and its receptors in mammalian CNS. Cytokine Growth Factor Rev 2004; 15: 147-156.
55. Wolff T. EGF receptor signaling: putting a new spin on eye development. Curr Biol 2003; 13: R813-R814.
56. Bieker R, Padro T, Kramer J, Steins M, Kessler T, Retzlaff S et al. Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. Cancer Res 2003; 63: 7241-7246.
57. Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, Gutkind JS et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998; 391: 86-89.
58. Whitman AG, Hamden KH, Ford PW, McCubrey JA, Akula SM. Role for Raf in the entry of viruses associated with AIDS. Int J Oncol 2004; 25: 469-480.
59. Shelton JG, Moye PW, Steelman LS, Blalock WL, Lee JT, Franklin RA et al. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 2003; 17: 1765-1782.
60. McCubrey JA, Steelman LS, Hoyle PE, Blalock WL, Weinstein-Oppenheimer C, Franklin RA et al. Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 1998; 12: 1903-1929.
61. Blalock WL, Pearce M, Chang F, Lee JT, Pohnert SC, Burrows C et al. Effects of inducible MEK1 activation on the cytokine dependency of lymphoid cells. Leukemia 2001; 15: 794-807.
62. Chang J, Renne R, Dittmer D, Ganem D. Inflammatory cytokines and the reactivation of Kaposi's sarcoma associated herpesvirus lytic replication. Virology 2000; 266: 17-25.
63. Ganem D. Human herpesvirus 8 and its role in the genesis of Kaposi's sarcoma. Curr Clin Top Infect Dis 1998; 18: 237-251.
64. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001; 1-2: 53-62.
65. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002; 25: 511-518.
66. Rapp UR, Goldsborough MD, Mark GE, Bonner TI, Groffen J, Reynolds Jr FH et al. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci USA 1983; 80: 4218-4222.
67. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
68. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-953.
69. V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004; 64: 2338-2342.
70. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003; 1653: 25-40.
71. O'Neill E, Kolch W. Conferring specificity on the ubiquitous Raf/MEK signaling pathway. Br J Cancer 2004; 90: 283-288.
72. Querbes W, Benmerah A, Tosoni D, Di Fiore PP, Atwood WJ. A JC virus-induced signal is required for infection of glial cells by a clathrin- and eps15-dependent pathway. J Virol 2004; 78: 250-256.
73. Wang X, Huong SM, Chiu ME, Raab-Traub N, Huang ES. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 2003; 424: 456-461.
74. Sharma-Walia N, Naranatt PP, Krishnan HH, Zeng L, Chandran B. Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 envelope glycoprotein gB induces the integrin-dependent focal adhesion kinase-Src-phosphatidylinositol 3-kinase-rho GTPase signal pathways and cytoskeletal rearrangements. J Virol 2004; 78: 4207-4223.
75. Akula SM, Ford PW, Whitman AG, Hamden KE, Shelton JG, McCubrey JA. Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection. Oncogene 2004; 23: 5227-5241.
76. Hoyle PE, Moye PW, Steelman LS, Blalock WL, Franklin RA, Pearce M et al. Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by MEK1-dependent mechanism. Leukemia 2000; 14: 642-656.
77. Ford PW, Whitman AG, Hamden KE, McCubrey JA, Akula SM. Vascular endothelial growth factor augments human herpesvirus-8 (HHV-8/KSHV) infection. Cancer Biol Ther 2004 (in press).
78. Hamden KH, Ford PW, Whitman AG, Dyson OF, McCubrey JA, Akula SM. Raf induced vascular endothelial growth factor augments Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) infection. J Virol (in press).
79. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003; 28 488-494.
80. Flaxenburg JA, Melter M, Lapchak PH, Briscoe DM, Pal S. The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J Immun 2004; 172: 7503-7509.
81. Ruhrberg C. Growing and shaping the vascular tree: multiple roles for VEGF. BioEssays 2003; 25: 1052-1060.
82. Cramer T, Schipani E, Johnson RS, Swoboda B, Pfander D. Expression of VEGF isoforms by epiphyseal chondrocytes during low-oxygen tension is HIF-1 alpha dependent. Osteoarthr Cartilage 2004; 12 433-439.
83. Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leukemia Res 2004; 28: 243-248.
84. Mercurio AM, Bachelder RE, Bates RC, Chung J. Autocrine signaling in carcinoma: VEGF and the alpha6beta4 integrin. Semin Cancer Biol 2004; 14: 115-122.
85. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9: 2-10.
86. Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Invest Dermatol Symp Proc 2000; 5: 24-33.
87. Fernando NH, Herwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003; 30: S39-S50.
88. Manley PW, Bold G, Brüggen J, Fendrich G, Furet P, Mestan J et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochem Biophys Acta 2004; 1697: 17-27.
89. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J et al. Discovery of 5-[5-flouro-2-oxo-1,2-dihydroin-dol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H -pyrrole-3-carboxylic Acid (2-diethylaminothyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003; 46: 1116-1119.
90. Hennequin LF, Stokes ESE, Thomas AP, Johnstone C, Ple PA, Ogilvie DJ et al. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 2002; 45: 1300-1312.
91. Bold G, Altmann K-H, Frei J, Lang M, Manley PW, Traxler P et al. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem 2000; 43: 2310-2323.
92. Manley PW, Martiny-Baron G, Schlaeppi JM, Wood JM. Anti-VEGF therapy. Expert Opin Biol Ther 2002; 11: 1715-1736.
93. Lowinger TB, Riedl B, Dumas J, Smith RA. Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des 2002; 8: 2269-2278.
94. Chen BC, Chang YS, Kang JC, Hsu MJ, Sheu JR, Chen TL et al. Peptidoglycan induces nuclear factor-kappaB activation and cyclooxygenase-2 expression via Ras, Raf-1, and ERK in RAW 264-7 macrophages. J Biol Chem 2004; 279: 20889-20897.
95. Hall-Jackson CA, Goedert M, Hedge P, Cohen P. Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene 1999; 18: 2047-2054.
96. Gibbs JB. Anticancer drug targets: growth factors and growth factor signaling. J Clin Invest 2000; 105: 9-13.
97. Cunningham CC, Holmlund JT, Schiller JH, Geary RS, Kwoh TJ, Dorr A et al. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2000; 6: 1626-1631.
98. Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003; 30: 105-116.
99. Kramer BW, Goetz R, Rapp UR. Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. BMC Cancer 2004; 4: 24.
100. Grundhoff A, Ganem D. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 2004; 113: 124-136.
101. Sirianni MC, Vincenzi L, Topino S, Scala E, Angeloni A, Gonnella R et al. Human herpesvirus 8 DNA sequences in CD8+ T cells. J Infect Dis 1997; 176: 541.